



4DMedical Limited Extraordinary General Meeting

Chair's Address Ms Lil Bianchi

10.00AM, Monday, 22 January 2024

Thank you for your time today.

We called this meeting following our acquisition of Imbio, funded by a capital raise.

Imbio is a U.S. MedTech recognised as a leader in lung and heart AI. Andreas and I will set out the importance of this acquisition during the meeting.

At our AGM I had the pleasure to speak to a number of you, and today we continue the dialogue online.

Since November 4DMedical has delivered on key initiatives. I want to share 5 highlights.

- Philips alliance
- US reimbursement
- Product distribution in ANZ
- US regulatory approval
- Acquisition of US based AI company

1. Philips alliance

A hardware provider alliance is an acceleration strategy offering extended reach, reduced deployment costs and access to technical and commercial expertise.

In November we were delighted to announce an MOU with Philips Healthcare. Philips is a global iconic company in medical imaging, with technology in 50% of U.S. Veterans Affairs clinics. Last week we signed a Team Agreement which offers a combined 4DM XV Technology and Philips hardware solution to VA clinics. XV will be added to Philips' product catalogue and provided through their Government sales team.

Meeting the needs of the VA alongside a proven, existing partner is a significant opportunity to accelerate our go-to-market ambitions in North America.

2. US reimbursement

Reimbursement is vital in the U.S. healthcare market, where 90% of the population is covered by private and public insurers; and typically Medicare's fee schedules set the benchmark for commercial payers to follow.



In November we achieved a major reimbursement milestone. We secured US\$299 per scan for Medicare & Medicaid Services schedule; providing health coverage to U.S. adults over 65 covering around 65m people.

This removes a barrier to accessing XV LVAS, reduces out-of-pocket payments, and is the key to adoption at over 4000 Medicare-certified hospitals across America.

This is tremendous news in itself and also a big step towards reimbursement across the wider U.S. healthcare system.

We are already leveraging commercial benefit via agreements with outpatient practices in Detroit and Memphis to deliver scans in the U.S. market. This adds community based access to our existing hospital distribution, and we anticipate further expansion across in 2024.

3. Product distribution in ANZ

Distribution is core to commercialisation. Prior to the AGM, we signed a distribution agreement with Integral Diagnostics, an ASX-listed imaging network operating across 71 sites. We have begun piloting in regional Victoria as the basis for expansion network wide. This builds on existing agreements to reach more clinicians, increased referrals and with joint marketing and engagement campaigns a wider revenue base.

The agreement with Integral brings in regional Australia; and through Integral's acquisition of 20 imaging clinics in New Zealand a bridgehead for geographic expansion.

4. US FDA regulatory approval

As shareholders know, conforming with US Food and Drug Administration regulatory controls is complex and fundamental for commercialisation.

In November 4DM announced FDA clearance from FDA for CT LVAS. This product is already the cornerstone of XV Technology rollout in Australia which has the highest density of CT imaging infrastructure in the world. FDA clearance means we can now access the US market which has 43 CT scanners per million population.

This also de-risks the path to clearance of CT: VQ; a product positioned for high impact in Nuclear Medicine diagnosis with no need for inhalation of radioactive contrast agent. CT VQ is a disruptor product for diagnosis of pulmonary embolism and assessment of conditions such as COPD.

5. Imbio acquisition

The use of AI is gaining ground now in medical imaging and has potential to revolutionise detection of respiratory conditions. 4DM identified strong commercial opportunity in building an integrated XV Technologies and AI product suite focused on lung diagnostics.

Therefore we were excited to acquire Imbio in December 2023. Imbio is a U.S MedTech recognised as a leader in lung and heart AI. Integrating 4DMedical with Imbio can deliver: both lung function and structure technologies, cost-efficiencies and for clients a 'one stop shop' to improve patient care.



Imbio's customer base can accelerate new customers for XV Technology products.

The five areas I've highlighted demonstrate progress 4DM is making against an ambitious strategy. Approval of the resolutions tabled today enable this significant progress to be sustained.

On behalf of the Board thank you for your registration and attendance today and I kindly seek your approval of the resolutions placed before you which have the full support of the 4DM board.